WRD is interested in establishing alliances to develop and access:
- Patient cohorts with high quality longitudinal molecular and phenotypic data and/or DNA and appropriately-consented, IRB-approved tissue samples for:
- clinical trials
- data mining
- biomarker studies
- genetic and pharmaco-genomic studies
- Systems Biology/Pharmacology
- Databases with high quality treatment and disease outcomes associated with genetic, metabolomic, proteomic, transcriptomic or epigenetic data
- Databases of searchable eQTLs, pQTLs across tissues
- Disease biology guided combination therapy design platforms
- Systems biology approaches and proven in silico tools to evaluate pharmacological perturbation and elucidate mechanisms of in vivo toxicity
- Mining of data for correlation and understanding of causality
- Breakthrough diagnostic technologies that also are highly quantitative, require minimal tissue and can be multiplexed.
- In vivo imaging technologies (including MRI, PET, CT, optical imaging technologies, imaging agents, genetically encoded tags, etc.) with particular interest in:
- Imaging agents for small and large molecule compound distribution studies
- Imaging agents monitoring physiological mechanisms and disease
- Analytical tools and technologies
- Ex vivo Tissue and Cell Analysis
- Circulating tumor cell and Nucleic Acid quantification and analysis
- Multiplexed flow cytometry for leukocyte analysis
- Automated IHC for tissue analysis (cancer, safety)
- Advanced ADME — related genotyping
- Physiological Biomarkers
- Technologies adding precision to pain management and treatment in pre-clinical and clinical studies
- EEG-based biomarker for assessment of central pharmacology
- iPS cell resources and technologies to generate iPS cells that may be used to enable Precision Medicine strategies
- Validated cell differentiation protocols
- iPS cells derived from sub populations with specific genotypic/phenotypic data
- Technology to create iPS cells in a rapid and reproducible fashion without insertional approaches
